LncRNA HULC作为多种恶性肿瘤潜在预后因子的荟萃分析

AMeta-analysis of studies using LncRNA HULC as a potential prognostic factor for multiple malignant tumors

目的探讨长链非编码RNA(LncRNA)肝癌高表达转录本(HULC)的表达情况与肿瘤临床预后的关系。方法根据制定的纳入和排除标准,检索Pub Med、Embase和Cochrane Library数据库,筛选符合标准的研究,采用Review Manager 5.3软件进行统计学分析。结果共检出292篇相关文献,根据纳入和排除标准及文献质量评估方法共筛选出8篇文献,样本量为772例患者。荟萃分析的合并效应量显示,与HULC低表达组患者相比,HULC高表达组患者的总生存期较短(HR=2.10,95%CI:1.55~2.86,P﹤0.001)。根据肿瘤种类、患者国籍、样本类型进行分层亚组分析,在非肝癌组、胃肠道肿瘤组、非胃肠道肿瘤组、中国人群组、组织样本组中得到了相似的结果。OR值的合并效应量显示,过表达的HULC与多种临床病理特征有关。结论 LncRNA HULC在多种人类肿瘤中呈现过表达,这预示着较短的总生存期和较差的临床病理分期。

Objective To investigate the relationship between long-chain non-coding RNA （LncRNA） HULC （highly- up-regulated in liver cancer） and the clinical prognosis in cancer. Method PubMed, Embase and Cochrane Library data- bases were searched using established inclusion and exclusion criteria to retrieve the relevant studies. Statistical analysis was performed using Review Manager 5.3 software. Result A total of 292 relevant publications were retrieved, and 8 of which were included according to inclusion/exclusion criteria and quality evaluation standard of literature. The sample size was 772 patients. The combined effect in Meta-analysis indicated, the overall survival time in HULC overexpression group was longer than that in HULC lowexpression group （HR=2.10, 95%CI：1.55 to 2.86, P〈0.001）. A subgroup analysis was performed using tumor type, patient nationality and sample type as stratification factors, and similar results were obtained in the non-hepatocellular carcinoma group, the gastrointestinal cancer group, the non-gastrointestinal cancer group, the Chinese patient group and the tissue sample group. The combined effect of OR value showed that overexpression of HULC was related to a variety of clinicopathological features. Conclusion LncRNA HULC is overexpressed in multiple human tumors, and indicates shorter overall survival time and worse clinical pathological stage.